SIGN UP
LOG IN
MARKET
ATRC
ATRC
Atricure
NASDAQ
37.00
+0.30
+0.82%
Opening 11:25 11/29 EST
OPEN
37.00
PREV CLOSE
36.70
HIGH
37.57
LOW
36.35
VOLUME
274.50K
TURNOVER
0
52 WEEK HIGH
59.61
52 WEEK LOW
32.27
MARKET CAP
1.75B
P/E (TTM)
-68.9013
1D
5D
1M
3M
1Y
5Y
JMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target
Benzinga · 40m ago
Atricure: Statement of changes in beneficial ownership of securities
Press release · 1h ago
AtriCure defended at UBS despite Medtronic’s rival product
Atricure shares traded higher in the pre-market after ubs defended the maker of the atriclip cardiac device. Analyst at ubs maintains a buy rating on the stock despite medtronic's rival product launch in the u.s. Ubs's reaction comes after a competitor announced a limited rollout of the penditure system.
Seeking Alpha · 2h ago
Where AtriCure Stands With Analysts
Atricure has an average price target of $52.8 with a high of $60.00 and a low of $49.00. In the last 3 months, 5 analysts have offered 12-month price targets for the company. The company has observed the following analyst ratings in the last quarter.
Benzinga · 4h ago
Needham Reiterates Buy on AtriCure, Maintains $49 Price Target
Benzinga · 6h ago
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Ambrx Biopharma (AMAM)
TipRanks · 10h ago
Needham says Medtronic could create overhang on AtriCure shares
Needham says medtronic's limited us launch of competing product could create overhang on atricure shares. Investment bank says only 50% of the market has been penetrated. Needham says it is maintaining a buy rating on the company's atriclip.
Seeking Alpha · 20h ago
Atricure’s Strong Market Position Justifies Buy Rating Despite New Competition
TipRanks · 21h ago
About ATRC
AtriCure, Inc. provides technologies for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain. The Company develops, manufactures and sells devices designed primarily for the surgical ablation of cardiac tissue, systems designed for the exclusion of the LAA and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers. Its ablation and left atrial appendage (LAA) management products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System.
Webull offers AtriCure Inc. stock information, including NASDAQ: ATRC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading ATRC stock methods without spending real money on the virtual paper trading platform.